Factor XI Antisense Oligonucleotides for Post-operative VTE and Intra-arterial Treatment for Stroke
Nathan and Amol want you to understand the following:
1. Factor XI is a promising treatment target for preventing VTE, with a recent study showing that an antisense oligonucleotide was more effective in reducing VTE and had less associated bleeding than enoxaparin.
2. Intra-arterial treatments for stroke with the latest generation of devices was found to be effective in patients with moderately symptomatic strokes due to large vessel occlusion.
Continuing Medical Education
Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.
The papers
HR Büller et al. Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. N Engl J Med. 2015 Jan 15;372(3):232-40. (PubMed).
OA Berkhemer et al. A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke. N Engl J Med. 2015 Jan 1;372(1):11-20. (PubMed).
Good stuff
Why doesn’t everyone get the flu vaccine? Freakonomics radio podcast. (iTunes).
Dr. Atul Gawande – 2014 Reith Lectures. (iTunes).
